MedTrace Logo

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

NCT07050173 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the:

1. Change in GSH in brain and blood levels through GGC supplementation.
2. Change in the cognitive function in RHI patients due to GGC supplementation.

Conditions

  • Repetitive Head Impacts

Interventions

DRUG

Gamma-glutamylcysteine (GGC)

400mg tablet orally (two times) per day.

Sponsors & Collaborators

  • Chuck Noll Foundation

    collaborator UNKNOWN

  • Pravat Mandal

    lead OTHER

Principal Investigators

  • Pravat K Mandal, PhD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-11-01
Completion
2027-12-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07050173 on ClinicalTrials.gov